250 related articles for article (PubMed ID: 23892411)
1. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
Cai X; Cao W; Ding H; Liu T; Zhou X; Wang M; Zhong M; Zhao Z; Xu Q; Wang L
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1579-89. PubMed ID: 23892411
[TBL] [Abstract][Full Text] [Related]
2. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
3. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
4. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Hirata K; Nagata N; Kato T; Okuyama Y; Andoh H; Takahashi K; Oba K; Sakamoto J; Hazama S; Mishima H
Anticancer Res; 2014 Jan; 34(1):195-201. PubMed ID: 24403462
[TBL] [Abstract][Full Text] [Related]
5. Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.
Cai X; Tian C; Wang L; Zhuang R; Zhang X; Guo Y; Lu H; Wang H; Li X; Gao J; Li Q; Wang C
Cancer Biol Ther; 2017 Mar; 18(3):186-193. PubMed ID: 28278081
[TBL] [Abstract][Full Text] [Related]
6. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
[TBL] [Abstract][Full Text] [Related]
7. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
8. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
[TBL] [Abstract][Full Text] [Related]
9. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
[TBL] [Abstract][Full Text] [Related]
10. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
[TBL] [Abstract][Full Text] [Related]
11. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
[TBL] [Abstract][Full Text] [Related]
13. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
Ann Oncol; 1998 Aug; 9(8):845-7. PubMed ID: 9789606
[TBL] [Abstract][Full Text] [Related]
14. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
15. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.
Hazama S; Nagashima A; Kondo H; Yoshida S; Shimizu R; Araki A; Yoshino S; Okayama N; Hinoda Y; Oka M
Cancer Sci; 2010 Mar; 101(3):722-7. PubMed ID: 20028383
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.
Hamada A; Aoki A; Terazaki H; Ito K; Yokoo K; Sasaki Y; Saito H
Ther Drug Monit; 2005 Aug; 27(4):536-8. PubMed ID: 16044114
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
[TBL] [Abstract][Full Text] [Related]
20. Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.
Liu JY; Qu K; Sferruzza AD; Bender RA
Anticancer Drugs; 2007 Jul; 18(6):693-6. PubMed ID: 17762398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
